CRIS Current Research Information System

VUKOTIC, RANKA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.549
AS - Asia 1.702
EU - Europa 1.603
AF - Africa 161
SA - Sud America 80
OC - Oceania 2
Totale 6.097
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.524
SG - Singapore 597
CN - Cina 393
VN - Vietnam 377
GB - Regno Unito 358
IT - Italia 292
SE - Svezia 263
DE - Germania 227
HK - Hong Kong 159
IN - India 87
IE - Irlanda 76
RU - Federazione Russa 75
NL - Olanda 63
FR - Francia 60
BR - Brasile 59
TG - Togo 47
UA - Ucraina 44
CI - Costa d'Avorio 42
ZA - Sudafrica 33
JO - Giordania 28
EE - Estonia 25
KR - Corea 24
BE - Belgio 22
NG - Nigeria 21
BG - Bulgaria 20
FI - Finlandia 16
GR - Grecia 15
CA - Canada 13
AR - Argentina 12
CH - Svizzera 11
JP - Giappone 11
PL - Polonia 10
SC - Seychelles 10
ID - Indonesia 8
MX - Messico 6
HR - Croazia 5
AT - Austria 4
ES - Italia 4
BD - Bangladesh 3
EC - Ecuador 3
LT - Lituania 3
MY - Malesia 3
AE - Emirati Arabi Uniti 2
CL - Cile 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
IR - Iran 2
KE - Kenya 2
RO - Romania 2
RS - Serbia 2
TR - Turchia 2
AL - Albania 1
AU - Australia 1
CG - Congo 1
CO - Colombia 1
DK - Danimarca 1
GT - Guatemala 1
GY - Guiana 1
IL - Israele 1
IQ - Iraq 1
KZ - Kazakistan 1
LB - Libano 1
MA - Marocco 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
SA - Arabia Saudita 1
TT - Trinidad e Tobago 1
TZ - Tanzania 1
UZ - Uzbekistan 1
VE - Venezuela 1
ZM - Zambia 1
Totale 6.097
Salva come PNG Salva come JPEG
Città #
Singapore 423
Southend 318
Ashburn 284
Fairfield 279
Chandler 245
Dong Ket 214
Hong Kong 156
Woodbridge 134
Seattle 133
Wilmington 124
Houston 117
Ann Arbor 114
Santa Clara 109
Cambridge 95
Princeton 78
Dublin 76
Beijing 64
Hefei 57
Boardman 54
Lomé 47
Bologna 46
Ho Chi Minh City 45
Abidjan 42
Dallas 38
Hanoi 38
Westminster 36
Nanjing 34
Los Angeles 31
Amman 28
Berlin 26
Padova 25
Florence 23
Brussels 22
New York 22
Seoul 22
Abeokuta 21
Buffalo 21
Redondo Beach 21
Munich 20
Sofia 20
Jacksonville 19
Bremen 18
Turin 18
Milan 17
Rome 16
Saint Petersburg 15
Jinan 13
San Diego 13
São Paulo 13
Guangzhou 12
Redmond 11
Tokyo 11
Falkenstein 9
Frankfurt am Main 9
Helsinki 9
Medford 9
Shenyang 9
Bern 8
Des Moines 8
Nanchang 8
Stockholm 8
Falls Church 7
Haiphong 7
Wuhan 7
Bengaluru 6
Jiaxing 6
London 6
Nuremberg 6
Shijiazhuang 6
Toronto 6
Turku 6
Yubileyny 6
Zhengzhou 6
Zola Predosa 6
Bühl 5
Changsha 5
Chicago 5
Da Nang 5
Dearborn 5
Jakarta 5
Lanzhou 5
Lucca 5
Mexico City 5
Ningbo 5
Norwalk 5
Redwood City 5
Shanghai 5
Warsaw 5
Brooklyn 4
Chengdu 4
Costa Mesa 4
Council Bluffs 4
Faenza 4
Hangzhou 4
Hebei 4
Mahé 4
Montreal 4
Moscow 4
Orem 4
Tianjin 4
Totale 4.154
Salva come PNG Salva come JPEG
Nome #
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 268
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 223
Clinical and serological profile of primary biliary cirrhosis in men. 217
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. 202
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 201
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. 196
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 193
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 191
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 187
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 180
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort 171
Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholi fatty liver disease: an Italian community-based population study. 169
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients. 157
Non-invasive measurement of HVPG using graph analysis based on dynamic contrast-enhanced ultrasound with ESAOTE MyLab: The CLEVER Study. 156
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 155
Hepatitis B virus and immune response. 154
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 152
Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma 151
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B. 149
Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B 147
The increase of Ribavirin dose improves sustained virological response in HCV-Genotype 1 patients with a partial response to PEG-Interferon and Ribavirin. 146
Impact of psychosocial status on liver transplant process 142
Non-alcoholic steatohepatitis and liver transplantation 141
De novo autoimmune hepatitis in liver transplant: State-of-the-art review 131
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 126
Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients 125
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 123
Liver stiffness predicts the development of portal hypertension related complications in advanced chronic liver disease 121
LI-RADS: a great opportunity not to be missed 114
Insights into cancer severity from biomolecular interaction mechanisms 109
Hepatitis C virus eradication in the elderly: The challenge worth a long-life elixir? 109
Uno studio retrospettivo su 590 soggetti: sintomi psichiatrici durante la terapia antivirale per l’epatite cronica C. 108
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 107
Bone marrow derived stem cells for the treatment of end-stage liver disease. 104
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 104
null 103
Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options 101
null 96
Psychiatric symptoms during antiviral therapy for chronic hepatitis C: a retrospective study on 590 subjects 90
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older 89
Familial intrahepatic cholestasis: New and wide perspectives 88
The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series 86
Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group 81
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 57
Totale 6.220
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.355
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.355
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021420 0 0 0 0 0 21 12 36 53 28 24 246
2021/2022848 88 41 36 50 73 51 21 45 31 73 220 119
2022/20231.015 94 165 60 138 70 82 21 35 186 25 98 41
2023/2024256 19 47 33 21 23 52 10 12 6 18 6 9
2024/2025987 40 109 75 107 153 65 50 32 25 60 38 233
2025/20261.172 238 148 206 179 297 104 0 0 0 0 0 0
Totale 6.220